Savient Pharmaceuticals, Inc. (SVNT) Reports First Quarter 2013 Financial Results
5/15/2013 7:11:20 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BRIDGEWATER, N.J., May 15, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. SVNT today reported financial results for the three months ended March 31, 2013. Net sales of KRYSTEXXA® (pegloticase) were $4.4 million for the first quarter of 2013, a 6% decrease from the fourth quarter of 2012 and a 43% increase over the first quarter of 2012.
Help employers find you! Check out all the jobs and post your resume.